Recombinant allergens: The present and the future

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1534-1543

  Jutel, Marek ^a   Solarewicz Madejek, Katarzyna ^a   Smolinska, Sylwia ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Allergen specific immunotherapy; Allergy; Hypoallergens; Recombinant allergens; Vaccines

Indexed keywords

EID: 84868299209     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22064     Document Type: Review

References (72)

1. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7; PMID:11591189; http://dx.doi.org/10.1046/j.1365-2222.2001.01161.x.
2. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al.; (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8; PMID:17620073; http://dx.doi.org/10.1111/j.1398- 9995.2007.01451.x.
3. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66:725-32; PMID:21466562; http://dx.doi.org/10. 1111/j.1398-9995.2011.02589.x.
4. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27, quiz 28-9; PMID:21211639; http://dx.doi.org/10.1016/j.jaci.2010.11.030.
5. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 177:1572-3; http://dx.doi.org/10.1016/S0140-6736(00)78276-6.
6. Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy 2011; 66:713-24; PMID:21320133; http://dx.doi.org/10.1111/j.1398-9995.2010.02541.x.
7. Grönlund H, Vrtala S, Wiedermann U, Dekan G, Kraft D, Valenta R, et al. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 2002; 107:523-9; PMID:12460198; http://dx.doi.org/10. 1046/j.1365-2567.2002.01535.x.
8. Ibarrola I, Sanz ML, Gamboa PM, Mir A, Benahmed D, Ferrer A, et al. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 2004; 34:303-9; PMID:14987312; http://dx.doi.org/10. 1111/j.1365-2222.2004.01859.x.
9. Marsh DG, Norman PS, Roebber M, Lichtenstein LM. Studies on allergoids from naturally occurring allergens. III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps. J Allergy Clin Immunol 1981; 68:449-59; PMID:6171586; http://dx.doi.org/10.1016/0091-6749(81)90199-8.
10. Cox L. Standardized allergen extracts: past, present and future. Expert Rev Clin Immunol 2005; 1:579-88; PMID:20477599; http://dx.doi.org/10.1586/ 1744666X.1.4.579.
11. Aalberse RC, Crameri R. IgE-binding epitopes: a reappraisal. Allergy 2011; 66:1261-74; PMID:21623828; http://dx.doi.org/10.1111/j.1398-9995.2011. 02656.x.
12. Casale TB, Stokes Jr. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127:8-15, quiz 16-7; PMID:21094518; http://dx.doi.org/10.1016/j. jaci.2010.10.034.
13. Bohle B, Breitwieser A, Zwölfer B, Jahn-Schmid B, Sára M, Sleytr UB, et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer)protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1)combines reduced allergenicity with immunomodulating capacity. J Immunol 2004; 172:6642-8; PMID:15153479.
14. Moldaver D, Larché M. Immunotherapy with peptides. Allergy 2011; 66:784-91; PMID:21507007; http://dx.doi.org/10.1111/j.1398-9995.2011.02610.x.
15. Zeiler T, Taivainen A, Rytkönen M, Rautiainen J, Karjalainen H, Mäntyjärvi R, et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997; 100:721-7; PMID:9438477; http://dx.doi.org/10.1016/S0091-6749(97)70264-1.
16. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4; PMID:21458656; http://dx.doi.org/10.1016/j.jaci.2011.02.016.
17. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13; PMID:16159631; http://dx.doi.org/10.1016/ j.jaci.2005.06.004.
18. Young RA, Davis RW. Yeast RNA polymerase II genes: isolation with antibody probes. Science 1983; 222:778-82; PMID:6356359; http://dx.doi.org/10. 1126/science. 6356359.
19. Thomas WR. The advent of recombinant allergens and allergen cloning. J Allergy Clin Immunol 2011; 127:855-9; PMID:21251702; http://dx.doi.org/10.1016/ j.jaci.2010.12.1084.
20. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM, et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J Exp Med 1988; 167:175-82; PMID:3335830; http://dx.doi.org/10.1084/jem.167.1.175.
21. Thomas WR, Stewart GA, Simpson RJ, Chua KY, Plozza TM, Dilworth RJ, et al. Cloning and expression of DNA coding for the major house dust mite allergen Der p 1 in Escherichia coli. Int Arch Allergy Appl Immunol 1988; 85:127-9; PMID:3276629; http://dx.doi.org/10.1159/000234488.
22. Fang KS, Vitale M, Fehlner P, King TP. cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc Natl Acad Sci U S A 1988; 85:895-9; PMID:3422469; http://dx.doi.org/10.1073/pnas.85.3.895.
23. Weber E, Hunter S, Stedman K, Dreitz S, Olivry T, Hillier A, et al. Identification, characterization, and cloning of a complementary DNA encoding a 60-kd house dust mite allergen (Der f 18)for human beings and dogs. J Allergy Clin Immunol 2003; 112:79-86; PMID:12847483; http://dx.doi.org/10.1067/mai.2003. 1602.
24. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends Mol Med 2010; 16:321-8; PMID:20605742; http://dx.doi.org/10. 1016/j.molmed.2010.04.008.
25. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergenbased concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999; 29:896-904; PMID:10383589; http://dx.doi.org/10.1046/j.1365-2222.1999.00653.x.
26. Knol EF, Knulst AC. Application of multiplexed immunoglobulin E determination on a chip in component-resolved diagnostics in allergy. Clin Exp Allergy 2010; 40:190-2; PMID:19912247; http://dx.doi.org/10.1111/j.1365-2222. 2009.03402.x.
27. Uermösi C, Beerli RR, Bauer M, Manolova V, Dietmeier K, Buser RB, et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010; 126:375-83; PMID:20624641; http://dx.doi.org/10.1016/j.jaci.2010.05.040.
28. Jahn-Schmid B, Sirven P, Leb V, Pickl WF, Fischer GF, Gadermaier G, et al. Characterization of HLA class II/peptide-TCR interactions of the immunodominant T cell epitope in Art v 1, the major mugwort pollen allergen. J Immunol 2008; 181:3636-42; PMID:18714038.
29. Ebner C, Szépfalusi Z, Ferreira F, Jilek A, Valenta R, Parronchi P, et al. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993; 150:1047-54; PMID:7678615.
30. Westritschnig K, Horak F, Swoboda I, Balic N, Spitzauer S, Kundi M, et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008; 38:260-7; PMID:18339006; http://dx.doi.org/10. 1111/j.1365-2362.2008.01938.x.
31. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002; 129:1-18; PMID:12372994; http://dx.doi.org/10.1159/000065179.
32. Egger M, Mutschlechner S, Wopfner N, Gadermaier G, Briza P, Ferreira F. Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view. Allergy 2006; 61:461-76; PMID:16512809; http://dx.doi.org/10.1111/j.1398-9995.2006.00994.x.
33. Gamboa PM, Sánchez-Monge R, Díaz-Perales A, Salcedo G, Ansótegui J, Sanz ML. Latex-vegetable syndrome due to custard apple and aubergine: new variations of the hevein symphony. J Investig Allergol Clin Immunol 2005; 15:308-11; PMID:16433216.
34. Blanco C. Latex-fruit syndrome. Curr Allergy Asthma Rep 2003; 3:47-53; PMID:12542994; http://dx.doi.org/10.1007/s11882-003-0012-y.
35. Sidenius KE, Hallas TE, Poulsen LK, Mosbech H. Allergen cross-reactivity between house-dust mites and other invertebrates. Allergy 2001; 56:723-33; PMID:11488665; http://dx.doi.org/10.1034/j.1398-9995.2001.056008723.x.
36. Hauser M, Roulias A, Ferreira F, Egger M. Panallergens and their impact on the allergic patient. Allergy Asthma Clin Immunol 2010; 6:1; PMID:20298513; http://dx.doi.org/10.1186/1710-1492-6-1.
37. Skamstrup Hansen K, Poulsen LK. Component resolved testing for allergic sensitization. Curr Allergy Asthma Rep 2010; 10:340-8; PMID:20628838; http://dx.doi.org/10.1007/s11882-010-0133-z.
38. Weber RW. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99:203-11; quiz 12-3, 31.
39. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002; 16:414-6; PMID:11790727.
40. Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38:1514-25; PMID:18564326; http://dx.doi.org/10.1111/j.1365-2222.2008.03042.x.
41. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, Krauth MT, et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005; 115:1010-6; PMID:15867859; http://dx.doi.org/10.1016/j.jaci.2004.12.1142.
42. Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000; 30:1076-84; PMID:10931114; http://dx.doi.org/10.1046/j.1365-2222.2000.00869.x.
43. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101(Suppl 2):14677-82; PMID:15310844; http://dx.doi.org/10.1073/pnas.0404735101.
44. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, König F, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005; 116:347-54; PMID:16083789; http://dx.doi.org/10.1016/j.jaci.2005.04.003.
45. Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007; 119:1013-6; PMID:17292956; http://dx.doi.org/10.1016/j.jaci.2006.12.661.
46. Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007; 179:5309-16; PMID:17911617.
47. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-60; PMID:19000581; http://dx.doi.org/10.1016/j.jaci.2008.09.017.
48. Winther L, Poulsen L, Robin B, Melac M, Malling H. Safety and Tolerability of Recombinant Bet v 1 (rBet v 1)tablets in sublingual immunotherapy (SLIT). J Allergy Clin Immunol 2009; 123(suppl):S215; http://dx.doi.org/10.1016/j.jaci.2008.12.822.
49. Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011; 66:775-83; PMID:21352238; http://dx.doi.org/10.1111/j.1398-9995.2011.02565.x.
50. Larché M. Peptide and recombinant immunotherapy. [xi.]. Immunol Allergy Clin North Am 2011; 31:377-89, xi; PMID:21530826; http://dx.doi.org/10. 1016/j.iac.2011.03.008.
51. Moldaver D, Larché M. Immunotherapy with peptides. Allergy 2011; 66:784-91; PMID:21507007; http://dx.doi.org/10.1111/j.1398-9995.2011.02610.x.
52. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:1470-6; PMID:16751015; http://dx.doi.org/10.1016/j.jaci.2006.01.040.
53. Larché M. Peptide immunotherapy for allergic diseases. Allergy 2007; 62:325-31; PMID:17298351; http://dx.doi.org/10.1111/j.1398-9995.2006. 01309.x.
54. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937-45; PMID:8982778; http://dx.doi.org/10.1093/intimm/8.12. 1937.
55. Norman PS, Ohman JL Jr., Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8; PMID:8970345.
56. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:222-31; PMID:10600332; http://dx.doi.org/10.1006/clim.1999.4795.
57. Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189:1885-94; PMID:10377184; http://dx.doi.org/10.1084/jem.189.12.1885.
58. Haselden BM, Larché M, Meng Q, Shirley K, Dworski R, Kaplan AP, et al. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol 2001; 108:394-401; PMID:11544459; http://dx.doi.org/10.1067/mai.2001.117460.
59. Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167:1734-9; PMID:11466398.
60. Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53; PMID:12114041; http://dx.doi.org/10.1016/S0140-6736(02)09332-7.
61. Alexander C, Ying S, B Kay A, Larché M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52-8; PMID:15649266; http://dx.doi.org/10.1111/j.1365-2222.2005.02143.x.
62. Alexander C, Tarzi M, Larché M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-74; PMID:16134993; http://dx.doi.org/10.1111/j.1398-9995.2005.00885.x.
63. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-54; PMID:9648701; http://dx.doi.org/10.1016/S0091-6749(98)70402-6.
64. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854-61; PMID:12704369; http://dx.doi.org/10.1067/mai.2003.1337.
65. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465-74; PMID:16630151; http://dx.doi.org/10.1111/j.1365-2222.2006.02469.x.
66. Crameri R, Kündig TM, Akdis CA. Modular antigentranslocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:568-73; PMID:19680120; http://dx.doi.org/10.1097/ACI. 0b013e3283310fdf.
67. Martínez-Gómez JM, Johansen P, Rose H, Steiner M, Senti G, Rhyner C, et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009; 64:172-8; PMID:19076537; http://dx.doi.org/10.1111/j.1398-9995.2008.01812.x.
68. Zaleska A, Soyer O, Eiwegger T, Bassin C, Sollner S, Palomares O, et al. Immune regulation by intralymphatic immunotherapy with modular allergentranslocation MAT vaccine. Allergy 2011; 66:1-104.
69. Focke M, Linhart B, Hartl A, Wiedermann U, Sperr WR, Valent P, et al. Non-anaphylactic surfaceexposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004; 34:1525-33; PMID:15479266; http://dx.doi.org/10.1111/j.1365-2222.2004.02081.x.
70. Saarne T, Neimert-Andersson T, Grönlund H, Jutel M, Gafvelin G, van Hage M. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66:255-63; PMID:20804464; http://dx.doi.org/10.1111/j.1398-9995.2010.02468.x.
71. Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-70 e6.
72. Valenta R, Niespodziana K, Focke-Tejkl M, Marth K, Huber H, Neubauer A, et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4; PMID:21458656; http://dx.doi.org/10.1016/j.jaci.2011.02.016.